Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2021-09-29 00:00:00 ET · period of report 2021-09-27 · accession 0001104659-21-120896 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2021-09-29 | 2021-09-27+ | CHRS | HEALY JAMES | Dir | S - Sale | $16.68 | -434.6K | 334.4K | -57% | -$7.25M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.0001 par value | 2021-09-28 | S | D | 48,329 | $17.17 | 286,076 | I See Footnote | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.43, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. (F2) The shares are held by Sofinnova Management VII, LLC. The Reporting Person is the managing member of Sofinnova Management VII, LLC. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Management VII, LLC. |
| 2 | Common | Common Stock, $0.0001 par value | 2021-09-29 | S | D | 286,076 | $16.12 | 0 | I See Footnote | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.905, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. (F2) The shares are held by Sofinnova Management VII, LLC. The Reporting Person is the managing member of Sofinnova Management VII, LLC. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Management VII, LLC. |
| 3 | Common | Common Stock, $0.0001 par value | 2021-09-27 | S | D | 100,150 | $18.06 | 334,405 | I See Footnote | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.17, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. (F2) The shares are held by Sofinnova Management VII, LLC. The Reporting Person is the managing member of Sofinnova Management VII, LLC. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Management VII, LLC. |